Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84744 trials found · Page 34 of 4238
-
New cord blood treatment tested for tough leukemia in adults
Disease control Not yet recruitingThe purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults. It will also learn about the safety and efficacy of the allogeneic, u…
Phase: EARLY_PHASE1 • Sponsor: The General Hospital of Western Theater Command • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Radiation challenge to standard bladder cancer treatment could prevent surgery
Disease control Not yet recruitingIn the UK 20,000 people develop urothelial bladder cancer each year with 75-80% having Non-Muscle Invasive Bladder Cancer (NMIBC). The current standard of care for patients with High Risk-NMIBC (HR-NMIBC) is either surgery to remove the tumour (transurethral resection of bladder …
Phase: PHASE3 • Sponsor: The Christie NHS Foundation Trust • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New hope for tough-to-treat lung cancer: experimental drug enters final testing phase
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Phase: PHASE3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
CAR-T showdown: new trial pits High-Tech cell therapy against standard care to stop Leukemia's return
Disease control Recruiting nowThis prospective, open-label randomized controlled trial compares CD19 CAR-T therapy with chemotherapy plus donor lymphocyte infusion (DLI) in 70 patients with Ph-negative B-cell acute lymphoblastic leukemia (B-ALL) who exhibited minimal residual disease (MRD) positivity (≥0.1% C…
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New 'Living Drug' trial aims to fight tough blood cancers
Disease control Not yet recruitingA Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1195E CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Neck surgery trial offers new hope for slowing Alzheimer's decline
Disease control Not yet recruitingThis multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial is to evaluate the efficacy and safety of deep cervical lymphatic venous anastomosis (DC-LVA) plus usual care versus usual care in reduing the score of clinical dementia rating-sum of boxes (…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Race against time: new drug aims to save brains up to a day after stroke
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose 25 mg) compared with placebo in patients with acute …
Phase: PHASE3 • Sponsor: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Experimental cell therapy targets Tough-to-Treat leukemia in adults
Disease control Recruiting nowA Multicenter Study of CD19 CAR-T Cells in the Treatment of Adult Patients With Primary Ph Chromosome Positive Acute Lymphoblastic Leukemia
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
New 'Living Drug' trial targets Tough-to-Treat blood cancers
Disease control Not yet recruitingThe aim of this study is to analyze the safety of BAFF-R Chimeric Antigen Receptor T-Cell Injection (BAFF-R CAR-T) in participants with relapsed/refractory BAFF-R-positive B-cell lymphoma and explore the Maximum Tolerated Dose (MTD). The secondary objective of this study is to e…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 06, 2026 14:05 UTC
-
New 'Living Drug' trial targets Tough-to-Treat blood cancers
Disease control Not yet recruitingTo Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.
Phase: PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New hope for women with Tough-to-Treat uterine cancer
Disease control Recruiting nowThe purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy.…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
Fighting skin cancer with your own supercharged immune cells
Disease control Recruiting nowThis is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New drug combo aims to extend lives in advanced prostate cancer
Disease control Recruiting nowThe primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New drug combo trial offers hope for advanced kidney cancer patients
Disease control Recruiting nowResearchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compar…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 06, 2026 14:16 UTC
-
New transplant approach aims to rebuild immune system in SCID patients
Disease control TerminatedBackground: Severe combined immune deficiency (SCID) is a group of conditions where the immune system does not work properly. The only cure for most SCIDs is a stem cell transplant (getting cells from a donor). These transplants can have serious complications. Before the transpl…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 13, 2026 20:09 UTC
-
New combo therapy aims to save bladders from cancer surgery
Disease control Recruiting nowThis phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy includes chemotherapy before surgery (neoadj…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
Major trial aims to boost chemo power against aggressive blood cancer
Disease control Recruiting nowThe purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
Phase: PHASE3 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
Major trial tests first drug aimed at slowing Parkinson's itself
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
New hope for patients with Life-Threatening immune storm
Disease control Recruiting nowA study designed to evaluate the efficacy, safety, immunogenicity, PK, and PD characteristics of Plonmarlimab in patients with relapsed/refractory rheumatic and immunologic disease-associated MAS, and to explore biomarkers related to the efficacy of Plonmarlimab.
Phase: PHASE3 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Ultrasound zaps kidney fat to fight stubborn high blood pressure
Disease control Not yet recruitingThe goal of this clinical trial is to investigate if focused power ultrasound (FPU) targeted perirenal adipose tissue modification therapy would be effective and safe in treating resistant hypertension. The primary outcome of the study is the difference in the reduction of 24h me…
Phase: PHASE3 • Sponsor: Yan Li • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC